LSE:GSKPharmaceuticals
GSK’s 35Pharma Deal Highlights Pulmonary Hypertension Bet And Pipeline Priorities
GSK (LSE:GSK) is acquiring Canadian biotech 35Pharma in a deal valued at nearly US$1b.
The transaction brings 35Pharma’s investigational activin signaling inhibitor HS235 into GSK’s pipeline.
HS235 is being developed for pulmonary arterial hypertension and related cardiopulmonary conditions.
For GSK, known for its focus on respiratory and specialty medicines, the 35Pharma deal adds another late stage cardiopulmonary asset alongside its existing portfolio. Pulmonary arterial hypertension...